atorvastatin has been researched along with evacetrapib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Krueger, KA; Morisaki, Y; Ruotolo, G; Takeuchi, M; Teramoto, T | 1 |
| Ballantyne, CM; Beacham, LA; Miller, DL; Nicholls, SJ; Nissen, SE; Ray, KK; Riesmeyer, JS; Ruotolo, G | 1 |
| Iimura, T; Kiyosue, A; Murakami, M; Riesmeyer, JS; Takita, Y; Teramoto, T | 1 |
| Chen, H; Chen, X; Chen, Y; Dong, J; Ge, J; Jiang, XC; Wang, L; Zhang, X | 1 |
| Carvajal-Gonzalez, S; Dullea, R; Furtado, JD; Nicholls, SJ; Ruotolo, G; Sacks, FM | 1 |
5 trial(s) available for atorvastatin and evacetrapib
| Article | Year |
|---|---|
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2014 |
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Biomarkers; Cholesterol Ester Transfer Proteins; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Time Factors; Treatment Outcome; United States | 2017 |
Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
Topics: Aged; Asian People; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Treatment Outcome | 2017 |
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein C-III; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Coronary Disease; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged | 2022 |
1 other study(ies) available for atorvastatin and evacetrapib
| Article | Year |
|---|---|
Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Diabetes Mellitus; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2019 |